NEWS

News Updates

Information Center


MA Achievement Release | Agomelatine Tablets Have Obtained Registration Approval!

2024-12-06


Congratulations to Chongqing Huasen Pharmaceutical Co., Ltd. on obtaining the registration certificate for the agomelatine tablet project.

MA Results Release | Huasen Pharmaceutical—Terazosin Hydrochloride Capsules Approved!

2022-03-23


Congratulations to Chongqing Huasen Pharmaceutical Co., Ltd. on receiving the “Drug Approval Notice” for its Terazosin Hydrochloride Capsules (2mg) project!

A New Beginning, a New Journey—Warmly Celebrating the Official Establishment of the Eurasia Huizhi Shanghai Office

2021-02-23


Due to the company's growth, Eurasia Huizhi (Beijing) Medical Research Co., Ltd. officially established a Shanghai office on February 19, 2021.

A seminar on a clinical study protocol for non-small cell lung cancer was successfully held.

2021-01-05


During the period of regular COVID-19 prevention and control, our company successfully held an online proposal discussion meeting!

Uniting Hearts and Combining Forces: Otaikang’s Internal Training Successfully Held

2020-09-25


From June 2 to 3, 2018, the Aotekang Group held an internal training session in Beijing, themed “Unite Hearts and Pool Strengths to Secure a Winning Future.”

A Phase I clinical trial for a Class 1.1 new drug from a listed company has been launched, with Eurasia Huizhi serving as the CRO.

2020-09-24


On April 5, 2019, the kickoff meeting for the Phase I clinical trial of a Class 1.1 new chemical drug project, a well-known listed company's drug, was held. Eurasia Huizhi (Beijing) Medical Research Co., Ltd. served as the contract research organization for this project.

< 1 > 跳转到

Leave a message for inquiry